
Loading, please wait...

Loading, please wait...

Corticobasal syndrome presents an extraordinary clinical challenge for modern neurology and geriatric medicine. Applying rTMS in corticobasal syndrome represents a pioneering therapeutic avenue for addressing refractory cortical manifestations. Corticobasal syndrome manifests with progressive asymmetric parkinsonism, dystonia, cortical sensory loss, and debilitating limb apraxia. Patients lose the capacity to execute purposeful gestures and skilled voluntary movements, despite retaining baseline muscular strength. Consequently, apraxia profoundly impairs activities of daily living, eating, and personal hygiene. Standard pharmacotherapies deliver virtually no clinical benefit for cortical deficits in this neurodegenerative disorder. Dopaminergic drugs typically fail to alleviate apraxia or halt frontoparietal neurodegeneration. Therefore, clinicians urgently require noninvasive neuromodulatory alternatives to restore disordered brain network dynamics. Low-frequency repetitive transcranial magnetic stimulation modulates cortical excitability through targeted magnetic fields. By suppressing hyperexcitable cortical circuits, repetitive stimulation promotes neuroplastic reorganization across damaged sensorimotor networks. Recent clinical data demonstrate that focal cortical neuromodulation can improve motor praxis and functional coordination. Specifically, applying inhibitory magnetic stimulation over the parietal cortex targets the neuroanatomical hub of praxis planning. Furthermore, noninvasive brain stimulation creates opportunities to alter disease trajectories without systemic adverse effects. Thus, neuromodulation offers renewed hope for patients battling severe atypical parkinsonism.
Neuropathological degeneration in corticobasal syndrome predominantly damages frontoparietal networks and subcortical basal ganglia structures. However, researchers have only recently characterized the precise biochemical alterations underlying apraxic symptoms. High-field proton magnetic resonance spectroscopy demonstrates a profound deficit of gamma-aminobutyric acid within the parietal cortex. Notably, this biochemical deficiency concentrates heavily on the cerebral hemisphere clinically most affected by the disease. Gamma-aminobutyric acid serves as the central nervous system's chief inhibitory neurotransmitter. When parietal GABAergic interneurons degenerate, surrounding sensorimotor networks experience significant disinhibition and unconstrained hyperexcitability. As a result, the cortex loses the inhibitory gating required to select and execute discrete motor programs. Clinicians observe this dysregulation clinically as severe ideomotor and limb-kinetic apraxia. Furthermore, parietal hyperexcitability impairs cross-modal integration of spatial coordinates and tactile inputs. Baseline neuroimaging confirms a direct relationship between marked GABA depletion and worsening apraxic severity. Because the parietal cortex coordinates skilled manual actions, biochemical restoring of inhibitory tone represents a crucial therapeutic goal. In addition, modulating neurotransmitter levels noninvasively provides mechanistic insights into neurodegenerative pathophysiology. Inhibitory magnetic stimulation can re-establish physiologic balance by dampening aberrant neuronal firing across cortical loops.
To investigate whether cortical neuromodulation could alleviate apraxia, investigators launched a prospective bicentric pilot study. The clinical trial enrolled eighteen patients suffering from moderate to severe corticobasal syndrome. Participants underwent twenty consecutive daily sessions of inhibitory repetitive transcranial magnetic stimulation. Technicians positioned the stimulation coil directly over the parietal cortex of the more severely affected hemisphere. In addition, fifteen participants completed specialized proton magnetic resonance spectroscopy scans before and after the intervention. Researchers utilized the Apraxia DATE battery to evaluate fine finger dexterity, meaningless gesture imitation, and oral praxis. Additionally, the clinical protocol assessed global motor disability, activities of daily living, and cognitive performance. Follow-up examinations spanned a comprehensive six-month post-intervention monitoring interval. This rigorous design enabled investigators to evaluate both immediate neurochemical adjustments and prolonged functional motor recovery. Importantly, all eighteen participants tolerated the daily magnetic stimulation sessions without serious adverse events or complications. No patient dropped out of the study due to procedural discomfort or headaches. Moreover, the high protocol adherence highlights the practical viability of delivering intensive outpatient neuromodulation. Thus, the protocol demonstrated exceptional clinical feasibility, safety, and compliance in this vulnerable patient population.
The interventional trial documented remarkable improvements in both behavioral performance and cerebral neurochemistry. Following twenty stimulation sessions, patients achieved statistically significant score increases on the DATE Pseudoword subtest. Furthermore, longitudinal assessments revealed profound improvements in the DATE Finger subtest four weeks after completing therapy. These manual dexterity gains translated into improved object manipulation and smoother finger movements in everyday life. Remarkably, post-intervention magnetic resonance spectroscopy demonstrated a statistically significant increase in parietal GABA concentrations. Local neurotransmitter levels rose toward physiological ranges in the stimulated parietal cortex. Moreover, statistical analyses revealed a positive correlation between rising GABA concentrations and improved scores on oral praxis testing. This biochemical reversal confirms that inhibitory stimulation effectively reactivated residual GABAergic networks. In addition, sustained clinical gains indicate that magnetic stimulation induces durable synaptic plasticity rather than temporary effects. Therefore, clinical recovery directly reflects tangible neurochemical restoration rather than transient placebo effects. Consequently, targeted magnetic stimulation provides a mechanistically verified intervention for otherwise untreatable cortical symptoms. By addressing underlying neurotransmitter deficits, clinicians can substantially attenuate debilitating apraxia in neurodegenerative diseases.
Beyond alleviating motor apraxia, the neuromodulation regimen produced significant and durable cognitive enhancements. Investigators tracked cognitive performance using the standardized CERAD-plus neuropsychological testing battery. Following the stimulation protocol, patients demonstrated significant score improvements on the Wordlist Recall memory test. Remarkably, these cognitive benefits remained statistically significant throughout the entire six-month follow-up period. Parietal networks maintain dense reciprocal connections with temporal memory structures and prefrontal executive circuits. Consequently, enhancing parietal inhibitory control optimizes larger distributed cognitive networks across the brain. This finding carries vital importance for clinical practitioners caring for atypical parkinsonian syndromes. In addition, preserving verbal memory empowers patients to maintain personal relationships and communicate care preferences. Neurologists currently lack pharmacological remedies capable of slowing progressive cognitive decline in corticobasal syndrome. Therefore, noninvasive magnetic stimulation delivers a valuable multifaceted therapeutic approach. Furthermore, these positive outcomes encourage clinicians to integrate neuromodulation into multidisciplinary neurorehabilitation pathways. Future randomized sham-controlled trials should examine extended maintenance protocols and combined rehabilitation regimens. Ultimately, targeted neuromodulation proves that surviving cortical pathways retain substantial neuroplastic reserve even during advanced neurodegenerative progression.
Inhibitory repetitive transcranial magnetic stimulation delivers targeted magnetic pulses to the affected parietal cortex. This stimulation restores depleted local gamma-aminobutyric acid levels and dampens pathological cortical hyperexcitability. Consequently, the normalization of cortical inhibitory networks improves sensorimotor integration, facilitating purposeful finger movements and motor speech articulation in affected individuals.
Gamma-aminobutyric acid provides critical inhibitory control across parietal sensorimotor circuits. In corticobasal syndrome, severe parietal GABA deficiency triggers uninhibited neural firing and disrupted motor planning. Restoring GABA concentrations through magnetic stimulation directly correlates with improved gesture execution and motor praxis, highlighting GABA deficiency as a reversible pathophysiological contributor to apraxia.
Researchers observed substantial and lasting improvements in verbal memory following parietal stimulation. Specifically, treated patients demonstrated enhanced performance on the CERAD-plus Wordlist Recall subtest. Remarkably, these cognitive benefits remained statistically significant throughout the six-month follow-up window, indicating that parietal neuromodulation promotes broad network-level plasticity and functional cognitive connectivity.
Disclaimer: This content is for informational and educational purposes only and should not be considered as medical advice. Always consult a qualified healthcare professional regarding any medical condition or treatment options. Refer to the latest local and national guidelines for clinical practice.
References

Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.


A pilot study shows that 20 sessions of inhibitory rTMS over the parietal cortex in corticobasal syndrome restore deficient cortical GABA+/Cr levels and significantly improve apraxia and verbal memory, offering a novel noninvasive neuromodulatory avenue for refractory neurodegenerative symptoms.
Today

A qualitative study evaluated the INCLUDE trial, a culturally tailored mobile diabetes prevention intervention. Findings highlight digital accessibility and community coaching as key facilitators, while time constraints and rigid dietary elements posed barriers, offering vital lessons for clinical practice.
Today

A large cohort study demonstrates that fetal growth restriction in a first pregnancy raises maternal cardiovascular risk within five years postpartum, including elevated rates of heart failure, stroke, and myocardial infarction. Clinicians must initiate proactive postpartum screening and cardiovascular prevention.
Today

An NHANES analysis reveals that meeting 24-hour movement guidelines significantly lowers the odds of cardiovascular disease, obesity, hypertension, and diabetes among adults with disabilities, emphasizing the power of combined physical activity, sleep, and limited sedentary time.
Today

A paired cadaveric study compared triple and quintuple percutaneous Achilles tendon lengthening. While quintuple hemisection showed numerically greater elongation, differences were not statistically significant.
Today

A randomized trial in California evaluated a grocery support program for low-income, chronically ill adults. The intervention improved nutrition security by 2.8%, increased vegetable intake, boosted mental health scores, and reduced cost-related healthcare delays by 3.8%, showing the power of food-as-medicine.
Today